JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

185.37 1.21

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

180.09

Max

185.57

Galvenie mērījumi
By Trading Economics
Ienākumi	-332M -277M
Pārdošana	-11M 994M
Peļņas marža	-27.816
Darbinieki	18,300
EBITDA	730K 198M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+7.76% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.2B 9.2B
Iepriekšējā atvēršanas cena	184.16
Iepriekšējā slēgšanas cena	185.37

Ziņu noskaņojums

By Acuity

21%

79%

67 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

117.16 / 144.77 Atbalsts un pretestība

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. apr. 00:00 UTC

Galvenie ziņu notikumi

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026. g. 22. apr. 23:33 UTC

Peļņas

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026. g. 22. apr. 22:40 UTC

Peļņas

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026. g. 22. apr. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:11 UTC

Peļņas

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026. g. 22. apr. 21:01 UTC

Peļņas

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026. g. 22. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026. g. 22. apr. 23:16 UTC

Peļņas

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026. g. 22. apr. 23:15 UTC

Peļņas

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026. g. 22. apr. 22:52 UTC

Peļņas

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026. g. 22. apr. 22:51 UTC

Peļņas

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026. g. 22. apr. 22:29 UTC

Peļņas

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026. g. 22. apr. 22:27 UTC

Peļņas

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026. g. 22. apr. 22:06 UTC

Tirgus saruna

Peļņas

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026. g. 22. apr. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:47 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:37 UTC

Peļņas

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026. g. 22. apr. 21:34 UTC

Peļņas

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026. g. 22. apr. 21:29 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:20 UTC

Tirgus saruna

Peļņas

Tesla Expands Manufacturing to Chips -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

7.76% augšup

Prognoze 12 mēnešiem

Vidējais 197.3 USD 7.76%

Augstākais 235 USD

Zemākais 160 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

67 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.